Maxim Group Remains Bullish on Celsion (CLSN) Following Announced Phase lll OPTIMA Study

Maxim Group reiterated a Buy rating and $9.00 price target on Celsion Corp (NASDAQ: CLSN) following the company's announced phase III OPTIMA study of lead compound ThermoDox.

Analyst Jason McCarthy commented, "Celsion announced that the phase III OPTIMA study of lead compound ThermoDox (heat-activated liposomal doxorubicin) for the treatment of primary liver cancer was highlighted in an oral presentation at the 7th AsiaPacific Primary Liver Cancer Expert ("APPLE") Meeting."

For an analyst ratings summary and ratings history on Celsion Corp click here. For more ratings news on Celsion Corp click here.

Shares of Celsion Corp closed at $1.30 yesterday.

You May Also Be Interested In

• Deutsche Bank Upgrades MSCI Inc. (MSCI) to Buy, 'Compelling entry point for long-term investors'
• Silvercorp Metals (SVM) PT Lowered to $6 at Roth/MKM
• Piper Sandler Downgrades Independent Bank Group (IBTX) to Underweight, 'Expectations of Slower NII Recovery'